To aim of this study is to determine the prevalence of Non-Alcoholic Fatty Liver Disease and Thyroid Dysfunction in Patients with Metabolic Syndrome.
- Conditions
- Health Condition 1: null- Patients with an established diagnosis of MetS as per the ATP III criteria and visiting the clinic as a part of their schedule
- Registration Number
- CTRI/2016/09/007270
- Lead Sponsor
- Abbott India Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 400
1.Male and female patients, aged 18 to 65 years inclusive
2.Patients with an established diagnosis of MetS as per the ATP III criteria and visiting the clinic as a part of their schedule
1.Patients with history of drug intake likely to cause NAFLD (e.g. aspirin, amiodarone, corticosteroids, methotrexate, 5-fluorouracil, tamoxifen, valproate, zidovudine, didanosine, diltiazem) or TD (e.g. interferon, molecular-targeted agents, amiodarone, thyroid hormone, anti-thyroid drugs, lithium, iodine, dopamine)
2.Patients with history of jejuno-ileal bypass or biliopancreatic diversion or extensive small bowel resection or total parenteral nutrition.
3.Evidence of other forms of chronic liver disease, suspected or confirmed hepatocellular carcinoma, known HIV positive
4.Female patients who are pregnant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Percentage of patients with NAFLD amongst the patients with MetS (diagnosed as per ATP III criteria), visiting the Endocrinology and Gastroenterology outpatient departments (OPD) in India. <br/ ><br>2.Percentage of patients with TD amongst the patients with MetS (diagnosed as per ATP III criteria), visiting the Endocrinology and Gastroenterology outpatient departments (OPD) in India.Timepoint: 8 months recruitment period
- Secondary Outcome Measures
Name Time Method 1.Demographic characteristics, clinical and laboratory profile of Indian patients with MetS. <br/ ><br>2.Percentage of patients categorized into high, intermediate and low probability for advanced fibrosis as per NFS <br/ ><br>3.Percentage of TD patients with hyperthyroidism, subclinical hyperthyroidism, hypothyroidism and subclinical hypothyroidism <br/ ><br> <br/ ><br>Due to word limit the remaining 4 secondary endpoints have not been captured.Timepoint: 6 months